Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

"Morphoceuticals is building a platform that has the potential to transform human health,” said Pomerantz. "I am proud to ...

EXCLUSIVE: New mum Zara was shattered when told she had bowel cancer, but a new drug trial at The Christie in Manchester has ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

The advanced heart failure market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical companies such as ...